AI
AVTX icon

Atom Investors’s Avalo Therapeutics AVTX Stock Holding History

Atom Investors’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51,194
Closed -$930K – 664
2025
Q4 		$930K Buy
+51,194
New +$864K 0.07% 306
2021
Q4 		– Sell
-10
Closed -$60K – 276
2021
Q3 		$60K Buy
+10
New +$81.1K ﹤0.01% 295
2019
Q3 		– Sell
-14
Closed -$220K – 287
2019
Q2 		$220K Buy
+14
New +$212K 0.01% 377

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Atom Investors's AVTX Position: Q1 2026 in Review

Atom Investors sold out of Avalo Therapeutics (AVTX) in Q1 2026, closing a stake of 51,194 shares — an estimated $930K sold.

Atom Investors first reported a position in AVTX in Q2 2019 and held it in 3 quarters. The position peaked at $930K in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Atom Investors reported no remaining Avalo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Atom Investors sold 51,194 Avalo Therapeutics shares in Q1 2026, an estimated $930K.
  • Atom Investors first reported a position in Avalo Therapeutics in Q2 2019 and held it in 3 quarters.
  • Atom Investors's Avalo Therapeutics position peaked at $930K in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.